XML 19 R10.htm IDEA: XBRL DOCUMENT
v3.22.2

Net Income Per Share | 6 Months Ended
--- | ---
Jun. 30, 2022
Earnings Per Share [Abstract] |
Net Income Per Share | 2. Net Income Per Share Basic net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock outstanding. Diluted net income per share attributable to Innoviva stockholders is computed by dividing net income attributable to Innoviva stockholders by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the “2023 Notes”), our convertible senior notes due 2025 (the “2025 Notes”) and our convertible senior notes due 2028 (the “2028 Notes”) using the if-converted method. Our convertible senior notes due 2025 (the “2025 Notes”) are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. Our current intent is to settle the principal amount of the 2025 Notes in cash upon conversion. The impact of the assumed conversion premium to diluted net income per share was historically computed using the treasury stock method. As the average market price per share of our common stock as reported on The Nasdaq Global Select Market was lower than the initial conversion price of $17.26 per share, there was no dilutive effect of the assumed conversion premium for the three and six months ended June 30, 2021. The dilutive EPS of the notes was approximately $0.01 and $0.03 per share, respectively, using t he if-converted method for the three and six months ended June 30, 2022 as a result of the adoption of ASU 2020-06. The following table shows the computation of basic and diluted net income per share for the three and six months ended June 30, 2022 and 2021:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(In thousands except per share data) |  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net income attributable to Innoviva stockholders, basic |  | $ | 939 |  |  | $ | 88,948 |  |  | $ | 16,712 |  |  | $ | 183,071 |
Add: interest expense on 2023 Notes |  |  | 570 |  |  |  | 1,163 |  |  |  | 1,591 |  |  |  | 2,367 |
Add: interest expense on 2025 Notes |  |  | 1,375 |  |  |  | — |  |  |  | 2,539 |  |  |  | — |
Add: interest expense on 2028 Notes |  |  | 1,709 |  |  |  | — |  |  |  | 2,093 |  |  |  | — |
Net income attributable to Innoviva stockholders, diluted |  | $ | 4,593 |  |  | $ | 90,111 |  |  | $ | 22,935 |  |  | $ | 185,438 |
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average shares used to compute basic net income per share attributable to Innoviva stockholders |  |  | 69,643 |  |  |  | 88,423 |  |  |  | 69,594 |  |  |  | 94,858 |
Dilutive effect of 2023 Notes |  |  | 4,866 |  |  |  | 12,189 |  |  |  | 7,511 |  |  |  | 12,189 |
Dilutive effect of 2025 Notes |  |  | 11,150 |  |  |  | — |  |  |  | 11,150 |  |  |  | — |
Dilutive effect of 2028 Notes |  |  | 9,955 |  |  |  | — |  |  |  | 6,360 |  |  |  | — |
Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan |  |  | 39 |  |  |  | 27 |  |  |  | 77 |  |  |  | 49 |
Weighted-average shares used to compute diluted net income per share attributable to Innoviva stockholders |  |  | 95,653 |  |  |  | 100,639 |  |  |  | 94,692 |  |  |  | 107,096 |
Net income per share attributable to Innoviva stockholders |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.01 |  |  | $ | 1.01 |  |  | $ | 0.24 |  |  | $ | 1.93 |
Diluted |  | $ | 0.05 |  |  | $ | 0.90 |  |  | $ | 0.24 |  |  | $ | 1.73 |
Anti-Dilutive Securities The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti-dilutive for the periods presented:
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
(In thousands) |  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Outstanding options and awards granted under equity incentive plan and employee stock purchase plan |  |  | 642 |  |  |  | 1,093 |  |  |  | 514 |  |  |  | 1,126 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI https://asc.fasb.org/topic&trid=2144383 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration